CORALVILLE, Iowa, Aug. 03, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty
pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its president and
chief executive officer, Travis C. Mickle, Ph.D., will present at the Canaccord Genuity 37th Annual Growth Conference
being held August 9-10, 2017, at the InterContinental Boston Hotel.
Details of KemPharm's presentation are as follows:
| Date: |
|
|
|
|
|
Thursday, August 10, 2017 |
| Time: |
|
|
|
|
|
2:00 PM (ET) |
| Location: |
|
|
|
|
|
InterContinental Boston Hotel, 510 Atlantic Ave., Boston, MA 02210 |
| Room: |
|
|
|
|
|
The New York Room |
The presentation will be webcast and available on the Investor Relations section of the Company's website at
http://investors.kempharm.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to
treat serious medical conditions through its LAT™ (Ligand Activated Therapy) platform technology. KemPharm utilizes its LAT™
platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other
central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug
of methylphenidate, but with differing extended-release profiles for the treatment of ADHD, and KP201/IR, an acetaminophen-free
formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201. For more information on
KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 jrando@tiberend.com jdrumm@tiberend.com Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 dcohen@kempharm.com
